Moderna Vaccine is prepared for use at the United States Military Vaccination Center at Camp Foster on April 28, 2021 in Ginovan, Japan.
Carl Court Getty Images
Shares of major vaccine makers Covid fell on Monday as an unprecedented wave of omicron contamination eased and new cases declined rapidly across the country.
Moderna fell more than 11%, the biggest drop in the S&P 500 on Monday. Pfizer fell almost 2% and its partner BioNTech – more than 9%. Novavax amounted to more than 11% and Johnson and Johnson decreased by more than 1%.
White House chief medical adviser Dr. Anthony Foci told The Financial Times last week that the U.S. is coming out of the “full-scale phase of the Covid-19 pandemic.”
According to data collected by Johns Hopkins University, the United States reports that on Sunday, an average of about 175,000 new Covid cases per day are detected in seven days, down 42% over the past week. On average, on January 15, the number of reported cases reached a pandemic peak – more than 800,000 per day.
The Covid vaccine from Moderna is the company’s only commercial product, so its stocks may decline further as demand for the vaccine decreases.
About 64% of the U.S. population is fully vaccinated with two injections of Pfizer or Moderna vaccines or a single dose of Johnson & Johnson, according to the Centers for Disease Control and Prevention.
While vaccinations are still being embraced by Americans, the national vaccination rate itself is growing much slower than before the pandemic.
It took just over two months last summer for the proportion of fully vaccinated Americans to increase from 40% to 50%, and then for another four months to reach 60%. Since December 6, it has grown by only four percentage points.
Vaccination from Covid increased in December as the states confirmed their first cases of the omicron variant, but have since dropped out. According to the latest figures, the U.S. has made an average of 443,000 shots a day in the past week CDC data available as of February 8, compared to a December high of more than 1.7 million shots per day and a peak of nearly 3.5 million shots per day in April.
The Food and Drug Administration on Friday postponed plans for a rapid release of Pfizer and BioNTech Covid for children under 5 years of age. The FDA originally planned to allow the first two doses of the three-dose vaccine as early as this month. However, Pfizer and the FDA have said they now plan to wait until data on the third dose is released in April.
Pfizer and BioNTech are also developing a vaccine against Covid that targets the omicron variant. CEO Albert Burla said the introduction of omicron would be ready in March, although it was unclear whether a new vaccine would be needed if cases continued to decline. Moderna has also begun clinical trials of omicron-specific amplifying injections.
The Novavax vaccine has not received FDA approval. In the event that public health conditions continue to improve, it is unclear what demand will be in the U.S. for the company’s vaccine after Novavax receives the regulatory green light.
In the relevant news, Moderna CEO Stefan Bansel last week sold 19,000 shares of the company for a total of $ 2.9 million and deleted his Twitter account after two years of inactivity, raising questions on the social media platform. Bancel sells the same number of shares weekly, according to securities documents.